Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
Apimeds Pharmaceuticals US Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Apimeds Pharmaceuticals US Inc 주요 수익원은 Aquaculture and Agriculture이며, 최신 수익 발표에서 수익은 13,169,135입니다. 지역별로는 Malaysia이 Apimeds Pharmaceuticals US Inc의 주요 시장이며, 수익은 13,178,101입니다.
Apimeds Pharmaceuticals US Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Apimeds Pharmaceuticals US Inc의 순손실은 $0입니다.